Literature DB >> 8184704

Sickle cell disease: screening, diagnosis, management, and counseling in newborns and infants. The Agency for Health Care Policy and Research.

A O Berg1.   

Abstract

The AHCPR guideline on sickle cell disease has several strengths and many weaknesses. For the practicing physician it is strongest in recommending medical management of infants with sickle cell disease but weakest on screening and education and counseling. The evidence-based methodology should have been presented in more detail. Until that occurs, family physicians are left with this guideline as a summary of expert opinions with variable documentation of the underlying science.

Entities:  

Mesh:

Year:  1994        PMID: 8184704

Source DB:  PubMed          Journal:  J Am Board Fam Pract        ISSN: 0893-8652


  5 in total

1.  Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Mary Kleyn; Kevin J Dombkowski
Journal:  Blood Adv       Date:  2019-05-28

2.  Antibiotic Prophylaxis for Children With Sickle Cell Anemia.

Authors:  Sarah L Reeves; Alison C Tribble; Brian Madden; Gary L Freed; Kevin J Dombkowski
Journal:  Pediatrics       Date:  2018-02-05       Impact factor: 7.124

3.  Hydroxyurea Initiation Among Children With Sickle Cell Anemia.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski
Journal:  Clin Pediatr (Phila)       Date:  2019-05-21       Impact factor: 1.168

Review 4.  Emerging point-of-care technologies for sickle cell disease screening and monitoring.

Authors:  Yunus Alapan; Arwa Fraiwan; Erdem Kucukal; M Noman Hasan; Ryan Ung; Myeongseop Kim; Isaac Odame; Jane A Little; Umut A Gurkan
Journal:  Expert Rev Med Devices       Date:  2016-11-22       Impact factor: 3.166

5.  Identifying sickle cell disease cases using administrative claims.

Authors:  Sarah Reeves; Erika Garcia; Mary Kleyn; Michelle Housey; Robin Stottlemyer; Sarah Lyon-Callo; Kevin John Dombkowski
Journal:  Acad Pediatr       Date:  2014-05-29       Impact factor: 3.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.